Earnings call transcript: IBEX Q3 2026 sees revenue beat, stock surges 15%

IBEX posted record Q3 FY2026 revenue of $164.4 million, up 16.8% year over year and above consensus by 5.48%, while adjusted EPS of $0.91 met expectations. Management raised full-year revenue guidance to $638 million-$642 million and adjusted EBITDA guidance to $82 million-$84 million, citing strong health tech growth, share gains, and a new AI partnership with Sierra. The stock jumped 15.56% after hours, reflecting strong investor response to the results and improved outlook.

Analysis

IBEX is turning the AI narrative from a threat into a distribution advantage: the market still prices “AI = fewer seats,” but management is effectively selling “AI = higher win rate + higher ARPU + stickier accounts.” The second-order effect is that incumbents built on labor arbitrage should see more pricing pressure and lower renewal confidence, while differentiated BPOs with implementation speed and domain data can pull share faster than the AI displacement model bites. That makes this less about generic CX and more about who owns the client relationship when AI is inserted into the workflow.

The real earnings quality improvement is mix, not just growth. Revenue shifting toward higher-margin geographies and verticals suggests the company is moving up the value chain, which should defend margins even if some human-seat volume is cannibalized. The near-term setup also includes a modest operating disruption from capacity adjustments, so the next print may have a cleaner top line than margin line; that creates an opportunity for a dip-buy if the market overfocuses on one-time restructuring noise.

For NVDA, the article is incrementally negative at the margin because it reinforces a selective, not broad-based, monetization path for AI. If enterprise AI adoption is increasingly routed through vertical-specific platforms and services vendors rather than direct model spend, the first-order beneficiary is not always the compute seller; that can compress the multiple if investors extrapolate every AI use case into incremental GPU demand. The consensus miss is assuming AI adoption is linearly additive to infrastructure spend, when in practice a chunk of value accrues to the workflow owner and integrator.

Key Decisions for Investors

• Long IBEX on any post-earnings consolidation over the next 1-3 weeks; use weakness toward the pre/post-earnings gap as entry. Risk/reward favors a 15-20% upside continuation if the market starts capitalizing AI attach as margin expansion, with downside contained if guidance holds.
• Buy IBEX call spread for the next 1-2 quarters, targeting the guide-up cycle into FY27. Structure for a 2:1 or better payoff, since the main risk is a near-term margin wobble from capacity and impairment charges rather than demand failure.
• Short a basket of legacy BPOs or CX outsourcers against long IBEX over 1-3 months. The thesis is that AI does not destroy outsourcing demand; it redistributes share toward firms that can combine automation + delivery speed, creating a relative winner/loser split.
• Tactically trim/hedge NVDA into strength if the tape starts treating this as another 'AI demand everywhere' read-through. The better hedge is a relative short of AI infra versus long application-level enablers, since monetization may migrate up the stack.
• Watch for confirmation in next quarter's margin commentary before adding aggressively. If adjusted EBITDA margin holds despite the mix shift, the stock can rerate; if margin slips more than expected, the AI story becomes a longer-dated thesis rather than a near-term multiple catalyst.